Chemical Name: N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate compound with 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate (1:1) trisodium Hemipentahydrate
Smiles: C[C@@H](C(OCC)=O)C[C@H](NC(CCC([O-])=O)=O)CC1=CC=C(C2=CC=CC=C2)C=C1.O=C(CCCC)N([C@H](C([O-])=O)C(C)C)CC3=CC=C(C4=C(C5=NN=N[N-]5)C=CC=C4)C=C3.[5/2H2O].[3Na]
A liquid chromatographic method for separation of sacubitril–valsartan and their stereoisomeric impurities
Lu Zhou, Liang Zou, Lili Sun, Hui Zhang, Wenkai Hui and Qiaogen Zou
Anal. Methods, 2018,10, 1046-1053
Quantification of potential genotoxic impurity in sacubitril/valsartan drug substance at ppm level by LC-MS/MS
Ravi Uppala, M.Arthanareeswari, S.Devikala,T.Pushpamalini, J. ArockiaSelvi
Materials Today: Proceedings Volume 14, Part 2, 2019, Pages 640-645
Experimental Design Approach in HPLC Method Development: Application for the Simultaneous Determination of Sacubitril and Valsartan in Presence of Their Impurities and Investigation of Degradation Kinetics
Bahia A. Moussa, Hanaa M. A. Hashem, Marianne A. Mahrouse & Sally T. Mahmoud
Chromatographia volume 81, pages139–156(2018)
Development and validation of a stability indicating UHPLC method for Sacubitril/Valsartan complex in the presence of impurities and degradation products
Pintu Prajapati, Dhara Bhayani, Priti Mehta.
J App Pharm Sci. 2020; 10(2): 97-107